KITE Stock

Kite Pharma (KITE) was a top stock pick based on predictive algorithm recommended to I Know First subscribers on June 15th for the 7-Day time horizon. KITE had a signal of 35.16 and a predictability of 0.13. In accordance with the algorithm, the company reported short-term capital gains of 12.79%.

Kite Pharma was part of the stock forecast that can be found in the “BioTech-Stocks” Package.

The full Top 10 BioTech Stocks forecast includes a daily prediction for a total of 20 stocks with bullish and bearish signals:

• Top ten biotech stocks picks to long
• Top ten biotech stocks picks to short

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer.

on June 16th, Adimab, LLC, the technology leader in the discovery of fully human antibodies and bispecifics, announced a new collaboration with Kite Pharma, Inc. Under the terms of the agreement, Adimab will use its proprietary platform to generate IgGs against multiple targets selected by Kite.

“Kite has established itself as a leader in the field of engineered autologous cell therapies, and we are excited to have the opportunity to work with them” said Tillman Gerngross, Chief Executive Officer and co-founder of Adimab. “Our platform can rapidly deliver a diverse panel of antibodies with varying affinities and ultra-high selectivity, Kite is focused on finding partnerships, such as this collaboration with Adimab, that help us establish a competitive advantage in the CAR-T space” said Margo Roberts, Ph.D., Chief Scientific Officer of Kite.

On top of that during the morning of June 22nd, Kite Pharma and Bluebird Bio announced a strategic collaboration to advance second generation TCR cell therapy products to treat HPV-associated cancers.